AAOMS Annual Meeting

Following a clinical trial testing its safety and efficacy, the FDA has approved a new oral treatment for patients with relapsing forms of multiple sclerosis.

After the clinical trial showed positive results, the first treatment option for adults with inflammatory arthritis in the spine has been approved.

After the clinical trial showed positive results, the first treatment option for adults with inflammatory arthritis in the spine has been approved.

After the clinical trial showed positive results, the first treatment option for adults with inflammatory arthritis in the spine has been approved.

The FDA has approved a new option for the treatment of men with certain forms of hypogonadism caused by specific medical conditions.

The new oral treatment for multiple sclerosis is indicated for patients with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The FDA has approved a new treatment option that is the first drug approved by the FDA specifically for the treatment of postpartum depression in adult women.

The FDA has approved a new treatment option that is the first drug approved by the FDA specifically for the treatment of postpartum depression in adult women.

The FDA has approved a new treatment option that is the first drug approved by the FDA specifically for the treatment of postpartum depression in adult women.

The FDA has proposed that restrictions on flavored electronic cigarettes be tightened, in response to recent data showing a dramatic increase in the use of electronic nicotine delivery system (ENDS) use...